Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Clin Cancer Res. 2012 Aug 2;18(19):5412–5426. doi: 10.1158/1078-0432.CCR-12-1780

Fig. 1. Experimental overview.

Fig. 1

Schematic of the systems biology approach used to identify novel determinants of resistance to 5-FU and oxaliplatin in CRC. Microarray profiling was carried out on sensitive and resistant in vitro models and clinical samples from responding and non responding patients. Genelists generated from the microarray data were analysed by pathway analysis and gene set enrichment analysis to identify key pathways mediating resistance to 5-FU and oxaliplatin. Candidate genes from the selected pathways were functionally assessed by RNAi screening. CA=constitutively altered, IP=inducible parental, IR=inducible resistant, FDR=false discovery rate.